According to incomplete statistics, the number of IND applications for new stem cell drugs in China has exceeded 30 in the first half of this year, showing a significant growth trend compared to the 39 applications for the whole of 2024.

Recently, Sumitomo Pharma of Japan and Racthera jointly announced that they have submitted an application for the production and marketing authorization of raguneprocel to the regulatory authorities.

At present, six stem cell therapy projects in China are in the critical Phase III clinical trial stage, which indicates that the field of stem cell drugs is experiencing an important turning point.

In the first half of 2025, a major piece of news emerged in China's regenerative medicine field: the total financing amount of iPSC (induced pluripotent stem cells, iPS cells) therapy companies surpassed that of T-cell therapy companies for the first time.

This article conducts a comprehensive review of domestic pipelines under research and development

In recent years, with breakthroughs in technologies such as gene editing, cell regeneration, and new preparations, global research teams have made multiple milestone advancements in the treatment of Parkinson's disease.

In the stem cell treatment regimens for Parkinson's disease, nasal inhalation administration (such as the nasal mucosa route) is the only delivery method that does not require invasive procedures.

In recent years, the development of induced pluripotent stem cell (iPSC) technology has been profoundly changing the way we explore the mysteries of the brain.